Current Report Filing (8-k)
February 03 2023 - 4:35PM
Edgar (US Regulatory)
0001034842
false
0001034842
2023-02-01
2023-02-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported): February 1, 2023
RIGEL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
0-29889 |
|
94-3248524 |
(Commission File No.) |
|
(IRS Employer Identification No.) |
|
|
|
611 Gateway Boulevard |
|
|
Suite 900 |
|
|
South San Francisco, CA |
|
94080 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (650) 624-1100
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of Each Class |
|
Trading
Symbol(s) |
|
Name of Each Exchange on
Which Registered |
Common Stock, par value $0.001 per share |
|
RIGL |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(b)
On February 1, 2023,
Wolfgang Dummer, M.D., Ph.D. informed Rigel Pharmaceuticals, Inc. (the “Company”) of his intention to resign from
his position as the Company’s Executive Vice President and Chief Medical Officer. Such resignation is expected to be effective as
of March 31st, 2023 (the “Separation Date”). The Company has initiated a replacement search for a new Chief Medical
Officer with substantial hematology-oncology experience. Dr. Dummer has agreed to continue in his role as Executive Vice President
and Chief Medical Officer through the Separation Date.
(e)
Subject to Dr. Dummer’s
continued services through the Separation Date and in exchange for a full general release of claims and continued compliance with his
Employee Confidential Information and Inventions Agreement, Dr. Dummer’s resignation will be deemed a Non-COC Qualifying Termination
under the terms of the Company’s Executive Severance Plan, a copy of which is attached as Exhibit 10.1 to the Company’s
Quarterly Report on Form 10-Q for the period ended on March 31, 2020.
Forward-Looking Statements
Statements in this report that are not strictly
historical in nature constitute “forward-looking statements.” Such statements include, but are not limited to the continuation
of Dr. Dummer as an employee of the Company and the replacement search for a new Chief Medical Officer with substantial hematology-oncology
experience. Any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements.
Forward-looking statements can be identified by words such as "plan", "potential", "may", "expect",
"will", “believe”, “intend” and similar expressions in reference to future periods. Forward-looking
statements are neither historical facts nor assurances of future performance. Instead, they are based on Rigel's current beliefs, expectations,
and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy
and other future conditions, and hence they inherently involve significant risks, uncertainties and changes in circumstances that are
difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements.
Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result
of these risks and uncertainties, which include, without limitation, risks detailed from time to time in Rigel's reports filed with the
Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 and
subsequent filings. Any forward-looking statement made by us in this report is based only on information currently available to us and
speaks only as of the date on which it is made. Rigel does not undertake any obligation to update forward-looking statements, whether
written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, and expressly
disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein,
except as required by law.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 3, 2023 |
RIGEL PHARMACEUTICALS, INC. |
|
|
|
|
By: |
/s/ Ray Furey, J.D. |
|
|
|
Ray Furey, J.D. |
|
|
|
Executive Vice President, General Counsel and Corporate Secretary |
Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
From Sep 2023 to Sep 2024